Operating cash flow of $78.3M converted to free cash flow of $77.1M in 2026Q3 (a 35.5% FCF margin), yet quarterly FCF margins ranging from -0.1% to 45.5% and $53.7M in dividends paid suggest cash generation is episodic and may be outpacing sustainable capital returns.
Nutex Health, Inc. (NUTX) cash flow statement — 13-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'11 | Dec'10 |
|---|
| Cash from Operations | 258.45M | 248.13M | 23.15M | 1.26M | 50.61M | 173.43M | 86.67M | 12.12M | -480.05K | -714.62K | -274.22K | 44.91K | -664.57K | -889.1K |
| Operating CF Margin % | - | 28.35% | 4.82% | 0.51% | 23.08% | 52.31% | 31.63% | 12.49% | -35.12% | -3084.79% | - | - | -26.08% | -70.21% |
| Operating CF Growth % | 52.38% | 971.64% | 1742.79% | -97.52% | -70.82% | 100.1% | 614.84% | 2625.71% | 32.82% | -160.6% | -710.65% | 106.76% | 25.25% | - |
| Net Income | 164.71M | 180.36M | 95.27M | -43.42M | -432.74M | 168.53M | 145.56M | 32.09M | -950.13K | 582.06K | -451.06K | -536.13K | -383.39K | 158.14K |
| Depreciation & Amortization | 21.62M | 20.53M | 18.97M | 17.59M | 13.13M | 7.66M | 5.9M | 2.48M | 522 | 535.02K | 473 | 662 | 5.92K | 1.5K |
| Stock-Based Compensation | 6.36M | 117M | 16.63M | 2.84M | 189.58K | 0 | 0 | 0 | 208.03K | 924.33K | 0 | 0 | 815 | 5.83K |
| Deferred Taxes | -4.16M | 17.08M | -13.13M | -5.71M | 5M | 0 | 0 | 0 | 0 | -115.22K | 0 | 0 | -184.19K | -161.39K |
| Other Non-Cash Items | -49.94M | 902K | 9.81M | 31.62M | 400.71M | -5.51M | 1.24M | -596.94K | -49.45K | -2.83M | -130.63K | 563.79K | 104.01K | -1.05M |
| Working Capital Changes | 56.32M | -87.74M | -104.4M | -1.66M | 64.32M | 2.75M | -66.02M | -21.85M | 310.99K | 193.65K | 307K | -116.58K | -207.73K | 161.39K |
| Change in Receivables | 44.76M | -89.32M | -173.41M | -4.58M | 58.08M | -6.62M | -71.23M | -24.74M | -82.09K | -4K | 0 | 56.7K | -144.7K | -67.91K |
| Change in Inventory | -1.99M | -16K | 540.77K | 142.7K | -719.11K | -1.09M | -825.77K | -486.27K | 127 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -5.72M | 37.85M | -10.72M | -2.25M | 9.69M | 6.27M | 6.23M | 1.63M | 402.25K | 119.22K | 187.03K | 77.79K | -63.03K | 229.3K |
| Cash from Investing | -14.02M | -5.24M | -2.67M | -11.24M | -4.34M | -36.98M | -61.19M | -31.23M | -116.96K | 2.05K | -9.99K | 1.83K | 18.1K | -477.69K |
| Capital Expenditures | -6.35M | -2.53M | -2.3M | -9.5M | -14.63M | -36.93M | -61.19M | -32.28M | 0 | 0 | 0 | 0 | -19.39K | -5.69K |
| CapEx % of Revenue | 0.8% | 0.29% | 0.48% | 3.83% | 6.67% | 11.14% | 22.33% | 33.25% | - | 0.01% | - | - | 0.76% | 0.45% |
| Acquisitions | 1.99M | 0 | -361.32K | -1.74M | 10.3M | -48.85K | 0 | 1.04M | -116.96K | -30.8K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -8.31M | -4.31M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.85K | -9.99K | 1.83K | 37.49K | -472K |
| Cash from Financing | -157.22M | -97.95M | 1.09M | -2.27M | -48.13M | -125.85M | -7.97M | 21.71M | 704.57K | 711.5K | 172.44K | -51.28K | 0 | 22.89K |
| Debt Issued (Net) | -18.15M | -19.44M | -7.4M | 2.65M | -5.59M | -3.22M | 41.27M | 35.57M | 337.27K | 461K | 48.47K | 0 | 0 | 0 |
| Equity Issued (Net) | -56.68M | -5M | 9.2M | 0 | 4.76M | 0 | 120K | 0 | 0 | 275K | 0 | 0 | 0 | 0 |
| Dividends Paid | -82.33M | -74.28M | -6.44M | -5.21M | -51.23M | -144.34M | -59.05M | -18.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -55.69M | -5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -67K | 767K | 5.73M | 298.03K | 3.93M | 21.71M | 9.69M | 5.05M | 367.3K | -24.5K | 123.98K | -51.28K | 0 | 22.89K |
| Net Change in Cash | 87.51M | 145.23M | 21.58M | -12.25M | -1.86M | 10.6M | 17.51M | 2.6M | 109.82K | -1.07K | -111.77K | -4.54K | -240.75K | -391.52K |
| Free Cash Flow | 252.1M | 245.6M | 20.85M | -8.24M | 35.97M | 136.51M | 25.48M | -20.15M | -480.05K | -714.62K | -274.22K | 44.91K | -683.97K | -894.79K |
| FCF Margin % | 31.65% | 28.06% | 4.34% | -3.33% | 16.4% | 41.17% | 9.3% | -20.76% | -35.12% | -3084.79% | - | - | -26.84% | -70.66% |
| FCF Growth % | 43.02% | 1077.94% | 353.02% | -122.91% | -73.65% | 435.67% | 226.46% | -4097.63% | 32.82% | -160.6% | -710.65% | 106.57% | 23.56% | - |
| FCF per Share | 35.80 | 36.35 | 4.09 | -1.87 | 8.50 | 34.54 | 5.94 | -4.87 | -0.07 | -0.17 | -0.13 | 0.02 | -0.57 | -0.75 |
| FCF Conversion (FCF/Net Income) | 1.53x | 3.51x | 0.44x | -0.03x | -0.12x | 1.31x | 0.82x | 0.58x | 0.17x | -1.23x | 0.04x | 0.54x | 1.73x | -5.62x |
| Interest Paid | 17.98M | 2.51M | 3.47M | 1.64M | 4.62M | 4.1M | 3.25M | 427.4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 44.53M | 72.81M | 798.99K | 849.36K | 8.23M | 335.34K | 181.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying NUTX stock.
Nutex Health, Inc. (NUTX) generated $248.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Nutex Health, Inc. (NUTX) generated $245.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Nutex Health, Inc. (NUTX) spent $2.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Nutex Health, Inc. (NUTX) returned $74.3M to shareholders via cash dividends and spent $5.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Cash conversion volatility
Metrics are mathematically derived from official filings.
Earnings Quality Swings With Cash Timing
According to reported quarterly figures, Nutex converted net income into operating cash flow at 1.95x in 2026Q3 and 0.52x in 2026Q2, a dispersion that suggests headline earnings are not a stable guide to cash generation across quarters.
The gap between net income and operating cash flow is the central signal here, and it swings in both directions, including negative operating cash flow in 2024Q4 despite $61.7M of reported net income. Working capital movements of roughly $50M to $100M per quarter appear to be doing much of the reconciling work, which may indicate that collections timing or claims accruals, rather than underlying profitability, are driving reported earnings. Investors should monitor whether conversion normalizes toward 1.0x over a full year, since persistent divergence would warrant further investigation into receivables quality.
Free Cash Flow Lumpy Rather Than Trending
Based on Nutex's reported figures, free cash flow margin moved from 35.5% in 2026Q3 to 15.0% in 2026Q2 and from -0.1% to 45.5% across adjacent quarters, a pattern that suggests cash generation is episodic rather than trend-driven.
Capital expenditure is minimal, running well below 1.5% of revenue in every period, so free cash flow essentially tracks operating cash flow and inherits its volatility. The absence of a steady FCF trajectory limits confidence in using recent quarters as a run-rate base. The stronger 2026 readings appear tied to working capital release rather than a demonstrable improvement in recurring cash earnings.
Working Capital Drives Quarterly Cash Swings
As reported in the quarterly cash flow statements, working capital changes ranged from a $108.6M drag in 2024Q4 to a $56.9M release in 2025Q4, indicating that receivables and claims timing dominate reported operating cash flow.
These magnitudes are large relative to quarterly operating cash flow, which suggests the cash profile depends heavily on the timing of collections from payers. The reported data does not break out receivables, inventory, or payables, so the specific driver cannot be confirmed from these figures. Management's collection performance warrants closer scrutiny, particularly given the provision for doubtful accounts typical of emergency-care operators.
Buybacks and Dividends Absorb Recent Inflows
According to the reported cash flow data, Nutex returned $53.7M through dividends in 2026Q3 and $31.7M through buybacks in 2026Q1, deploying cash in a way that appears to follow strong collection quarters.
Capital returns appear to be timed to periods of elevated operating cash flow, which may reflect a policy of distributing windfall collections rather than a fixed payout framework. Acquisition outflows are small and sporadic, suggesting the company is not currently relying on purchased growth to sustain its revenue trajectory. Whether these distributions remain affordable depends on whether the cash conversion pattern proves durable, which the data does not yet establish.
Stock-Based Compensation Flatters Reported Cash
Based on reported figures, stock-based compensation ranged from $2.0M to $78.7M per quarter, and in 2025Q2 it exceeded the entire operating cash flow of $27.3M, suggesting cash flow may be overstated relative to economic cost.
Because SBC is a non-cash add-back, quarters with large SBC inflate the operating cash flow line relative to economic earnings, which may obscure the true cost of employee compensation. The 2025Q2 spike and the negative 2026Q1 SBC entry both warrant further investigation into the accounting treatment. Investors should examine whether SBC levels are sustainable and how they are reconciled against the cash-based view of profitability.